Two preclinical advances aim to extend CAR‑T efficacy to solid tumors. Columbia University researchers engineered HLA‑independent T (HIT) receptors that detect vanishingly low CD70 expression and eradicated kidney, ovarian and pancreatic tumors in models; the work was published in Science. Separately, a separate study showed that knocking out dual prostaglandin E2 receptors in engineered CAR‑T cells suppresses PGE2‑mediated immunosuppression and boosts antitumor potency. Both approaches spotlight strategies to overcome antigen scarcity and tumor microenvironment barriers that have hindered CAR‑T in solid cancers.